BioTuesdays

Category - Markets

Generation Bio

WB cuts Generation Bio to market perform

William Blair downgraded Generation Bio (NASDAQ:GBIO) to “market perform,” citing variability in a non-human primate study in Factor VIII production for its hemophilia program.  In mid-morning trading, the stock was...

Zymeworks Logo

SVB Leerink ups Zymeworks to OP from MP

SVB Leerink upgraded Zymeworks (NYSE:ZYME) to “outperform” from “market perform,” citing a sell-off in the stock that “makes us more constructive, despite some uncertainties.” The stock closed at $16.12 on Dec. 9.  ...

Delcath-Systems-Inc

HCW starts Delcath Systems at buy; PT $25

H.C. Wainwright initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and 12-month price target of $25. The stock closed at $8.02 on Dec. 9. Delcath is a clinical-stage interventional oncology company...

Apollo Endosurgery

Stifel starts Apollo Endosurgery at buy; PT $12

Stifel launched coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and $12 price target. The stock closed at $8.59 on Dec. 8. Apollo Endosurgery is a medical technology company focused on design...

Bolt-Biotherapeutics

Stifel cuts Bolt Biotherapeutics PT to $19 from $34

Stifel reduced its price target for Bolt Biotherapeutics (NASDAQ:BOLT) to $19 from $34, but maintained its “buy” rating, after the company presented interim clinical data from an ongoing Phase 1/2 study of BDC-1001, its...

NeuroOne

AGP starts NeuroOne Medical at buy; PT $5.75

Alliance Global Partners launched coverage of NeuroOne Medical Technologies (NASDAQ:NMTC) with a “buy” rating and price target of $5.75. The stock closed at $2.09 on Dec. 2. NeuroOne’s flexible, thin-film...

AcelRx Pharma Logo

Cantor cuts AcelRx PT to $4 from $9; maintains OW

Cantor Fitzgerald reduced its price target for AcelRx Pharmaceuticals (NASDAQ:ACX) to $4 from $9, but maintained its “overweight” rating, citing a revised ramp in Dsuvia sales, as well as recent acquisitions and an...

Point Biopharma

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...

Citius Logo

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.